ANALYSIS OF REFERENT AND GENERIC DRUGS OF AZELAIC ACID IN TERMS OF THE HYDRODYNAMIC RADIUS OF PARTICLES AND ZE7A-P0TENTIAL


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Relevance. In recent years, medicinal plants that serve as a source of antithyroid medicines have been of scientific interest for research. Such plants include Lycopuseuropaeus L., from the herb of which a dry extract with a pronounced thyrostatic effect was obtained in the Research Institute of Medicinal and Aromatic Plants. Because the violation of all types of metabolism in hyperthyroidism is one of the reasons for the development of secondary induced immunodeficiency, it was relevant to study the effect of the dry extract Lycopuseuropaeus L. on the functional state of the immune system of experimental animals. The aim is to study the immunotoxicity and allergenicity of a new antithyroidmedicine created on the basis ofthe herb dry extract Lycopuseuropaeus L. Material and methods. The choice of methods for studying the allergenicity and immunotoxicity of the herb dry extract Lycopuseuropaeus L. was determined by the requirements set out in the"Guidelines for conducting preclinical studies of Medicines". Experiments were performed on albino guinea pigs (males, body weight 350-400 g), CBA/Lac and BALB/c mice (males, body weight 18-20 g). In this study, albino guinea pigs, CBA/Lac and BALB/c mice were administered the test extract at doses of 10 and 100 mg / kg in the form of 0,1 and 1,0% aqueous solutions. Control animals received equivalent volumes of isotonic NaCl solution. The potential allergenic properties of test extractwere evaluated using the following tests: general systemic reactions, active cutaneous anaphylaxis, and delayed-type hypersensitivity reactions. The effect of the herb dry extract Lycopuseuropaeus L. on humoral immunity was evaluated by the test of antibody-forming cell generation in the spleen and the titer of hemagglutinins in the blood serum of mice. The effect of test extract on the state of T-cell immunity was studied by the delayed-type hypersensitivity reaction induction test in CBA/Lac mice. Results. When studying the potential allergenic properties of the herb dry extract Lycopuseuropaeus L. in experiments on different types of laboratory animals, no statistically significant differences in the results between the control and experimental groups were revealed. It was shown that, under different schemes of introduction, the studied extract stimulated effectors of cellular immunity in CBA/Lacmice at a dose of 100 mg/kg. Conclusion. The herb dry extract Lycopuseuropaeus L. does not induce allergic reactions. The extract stimulates the cellular immune response and may reduce the risk of secondary immunodeficiency in patients with thyroid pathology.

Full Text

Restricted Access

About the authors

M. S Nesterov

Scientific Center of Biomedical Technologies of the Federal Medical and Biological Agency of Russia

Email: mdulya@gmail.com
Head ofthe Laboratory of Bioanalytical Research Moscow region, Krasnogorsky district, village Bright mountains, Russia

D. V Khvostov

V.M. Gorbatov Federal Research Center for Food Systems, Russian Academy of Sciences

Email: daniil_hvostov@mail.ru
Junior Research Scientist, the Laboratory of Molecular Biology and Bioinformatics

R. A Ageldinov

Scientific Center of Biomedical Technologies of the Federal Medical and Biological Agency of Russia

Email: ageldinov@gmail.com
Research Scientist, Laboratory for Bioanalytical Research Moscow region, Krasnogorsky district, village Bright mountains, Russia

References

  1. Федеральные клинические рекомендации по ведению больных акне / под ред. А.В. Самцова, Е.Р. Аравийской. Москва, 2013. 20 с
  2. Hollnick H.P., Zouboulis C.C. Not all acne is acne vulgaris. Dtsch Arztebl Int 2014; 111: 301-312.
  3. Pawin H., Chivot M., Beylot C., et al. Living with acne. A study of adolescents’personal experiences. Dermatology. 2007; 215(4):308-314.
  4. Franzke N., Zimmer L, Schafer I., Radermacher C., Kresken J., Augustin M. Quality of medical care of patients with acne vulgaris in Germany - nationwide survey of pharmacy clients. J Dtsch Dermatol Ges. 2009; 7: 1060-1063.
  5. Nast A., Dreno B., Bettoli V., et al. European evidence-based (S3) guidelines for the treatment of acne. J Eur Acad Dermatol Venereol. 2012; 26(Suppl 1): 1-29.
  6. Fitton A., Goa K.L. Azelaic acid. A review of its pharmacological properties and therapeutic efficacy in acne and hyper-pigmentary skin disorders. Drugs. 1991; 41(5):780-798.
  7. Caprilli F., Mercantini R., Nazzaro-Porro M., et al. Studies of the genus Pityrosporum in submerged culture. Mycopathologia et Mycologia Applicata. 1973; 51:171-189.
  8. Nazzaro-Porro M., Passi S. Identification of tyrosinase inhibitors in cultures of Pityrosporum. J Invest Dermatol. 1978; 71:205-208.
  9. Nguyen Q.H., Bui T.P. Azelaic acid: pharmacokinetic and pharmacodynamics properties and its therapeutic role in hyperpigmentary disorders and acne. Int. J. Dermatol. 1995; 34(2):75-84.
  10. Nazzaro-Porro M., Passi S., Picardo M., et al. Beneficial effect of 15% azelaic acid cream on acne vulgaris. Br. J. Dermatol. 1983; 109:45-48.
  11. Mastrofrancesco A., Ottaviani M., Aspite N., Cardinali G., Izzo E., et al. Azelaic acid modulates the inflammatory response in normal human keratinocytes through PPARy activation. Exp. Dermatol. 2010; 19: 813-820.
  12. Briganti S., Flori E., Mastrofrancesco A., Kovacs D., Camera E., et al. Azelaic acid reduced senescencelike phenotype in photo-irradiated human dermal fibroblasts: possible implication of PPARy. Exp. Dermatol. 2013; 22: 41-47.
  13. Akamatsu H., Komura J., Asada Y., Miyachi Y., Niwa Y. Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases. Arch. Dermatol. Res 1991; 283: 162-166.
  14. Passi S., Picardo M., De Luca C., Breathnach A.S., Nazzaro-Porro M. Scavenging activity of azelaic acid on hydroxyl radicals ‘in vitro’. Free Radic. Res. Commun. 1991; 11: 329-338.
  15. Leeming J., Holland K., Bojar R. The in vitro antimicrobial effect of azelaic acid. Br. J. Dermatol. 1986; 115:551-556.
  16. King K., Leeming J., Holland K., Cunliffe W. The effect of azelaic acid on cutaneous micro flora in vivo and in vitro. J. Invest. Dermatol 1985; 84: 438.
  17. Ozkan M., Durmaz G., Sabuncu I., Saracoglu N., Akgun Y., Urer S. Clinical efficacy of topical clindamycin phosphate and azelaic acid on acne vulgaris and emergence of resistant coagulase-negative Staphylococci. Turk. J. Med. Sci. 2000; 30: 483-487.
  18. Maple P.A., Hamilton-Miller J.M., Brumfitt W. Comparison of the in-vitro activities of the topical antimicrobials azelaic acid, nitrofurazone, silver sulphadiazine and mupirocin against methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 1992; 29:661-668.
  19. Bladon P.T., Burke B.M., Cunliffe W.J., Forster R.A., Holland K.T., King K. Topical azelaic acid and the treatment of acne: a clinical and laboratory comparison with oral tetracycline. Br. J. Dermatol. 1986; 114: 493-499.
  20. Cunliffe W.J., Holland K.T. Clinical and laboratory studies on treatment with 20% azelaic acid cream for acne. Acta Derm. Venereol. Suppl. (Stockh) 1989; 143: 31-34.
  21. Farag A., Ananieva L. Acne vulgaris: ultrastructure changes after treatment with 20% azelaic acid. J. Dermatolog. Treat. 1995; 6: 151-154.
  22. Bojar R.A., Cutcliffe A.G., Graupe K., Cunliffe W.J., Holland K.T. Follicular concentrations of azelaic acid after a single topical application. Br. J. Dermatol. 1993; 129: 399-402.
  23. Bojar R.A., Cunliffe W.J., Holland K.T. Disruption of the transmembrane pH gradient - a possible mechanism for the antibacterial action of azelaic acid in Propionibacterium acnes and Staphylococcus epidermidis. J. Antimicrob. Chemother. 1994; 34: 321-330.
  24. Bojar R.A., Holland K.T., Cunliffe W.J. The invitro antimicrobial effects of azelaic acid upon Propionibacterium acnes strain P37. J. Antimicrob Chemother. 1991; 28: 843-853.
  25. Bojar R.A., Cutcliffe A.G., Graupe K., Cunliffe W.J., Holland K.T. Azelaic acid: a review of its antimicrobial properties. Rec Contemp Pharmacother. 1993; 4: 403-414.
  26. Gollnick H., Mayer-da-Silva A., Orfanos C.E. Effects of azelaic acid on filaggrin, other cytokeratins and on the ultrastructure of human keratinocytes in vivo. J. Invest. Dermatol. 1987; 89:452.
  27. Barbareschi M., Hendricks I., Angius A., Cattaneo M., Monti M. The anticomedonic activity of azelaic acid investigated by means of scanning electron microscopy on horny layer biopsy. J. Dermatolog. Treat. 1991; 2: 55-57.
  28. Geier G., Hauschild T., Bauer R., Kreysel H. Der Einfluss von Azelainsaure auf das Wachstum von Melanomzellkul-turen im Vergleich zu Fibroblastenkulturen. Hautarzt. 1986; 37: 146-148.
  29. Zaleski-Larsen L.A., Fabi S.G., McGraw T., Taylor M. Acne Scar Treatment: A Multimodality Approach Tailored to Scar Type. Dermatol Surg. 2016; 42(2): 139-149.
  30. Galhaup I. Azelaic acid: mode of action at cellular and sub-cellular levels. Acta Derm. Venereol. [Suppl.] (Stockh). 1989; 143: 75-82.
  31. Passi S., Picardo M., Mingrone G., et al. Azelaic acid: biochemistry and metabolism. Acta Derm. Venereol. [Suppl.] (Stockh). 1989; 143: 8-13.
  32. Breathnach A., Nazzaro-Porro M., Passi S., Zina G. Azelaic acid therapy in disorders of pigmentation. Clinics Dermatol. 1989; 7: 106-119.
  33. Iraji F., Sadeghinia A., Shahmoradi Z., Siadat A.H., Jooya A. Efficacy of topical azelaic acid gel in the treatment of mild-moderate acne vulgaris. Indian J. Dermatol. Venereol. Leprol. 2007; 73: 94-96.
  34. Angius A.G., Barbareschi M., Cattaneo M., Monti M., Caputo R. Evaluation of the anticomedo effect of azelaic acid using the technique of horny layer biopsy and scanning electron microscopy (in Italian). G. Ital. Dermatol. Venereol. 1990; 125: XXXIII-XXXVI.
  35. Katsambas A., Graupe K., Stratigos J. Clinical studies of 20% azelaic acid cream in the treatment of acne vulgaris. Comparison with vehicle and topical tretinoin. Acta Derm. Venereol. Suppl. (Stockh). 1989; 143: 35-39.
  36. Krishna G., Kligman A.M., editors. Acne and Rosacea, 3rd ed. Berlin, Germany: Springer-Verlag; 2000. 756 p.
  37. Krishna S., Kim C., Kim J. Innate immunity in the pathogenesis of acne vulgaris. In: Shalita A.R., Del Rosso J.Q., Webster G.F., editors. Acne Vulgaris. London: Informa Healthcare; 2011: 12-27.
  38. Stamatiadis D., Bulteau-Portois M.C., Mowszowicz I. Inhibition of 5a-reductase activity in human skin by zinc and azelaic acid. Br. J. Dermatol. 1988; 119: 627-632.
  39. Limburg J., Zettergren J., Swanson J., et al. Topical effect of 6-Methylene progesterone and azelaic acid on hamster ear sebaceous gland lipogenesis and morphology. J. Invest. Dermatol. 1989; 92: 472.
  40. Rach P., Topert M. Pharmacological investigation of azelaic acid. J. Invest. Dermatol. 1986; 86: 327.
  41. Gollnick H.P., Krautheim A. Topical treatment in acne: current status and future aspects. Dermatology. 2003; 206: 29-36.
  42. Passi S., Nazzaro-Porro M., Picardo M., et al. Metabolism of straight saturated medium chain length C9 to C12 dicarboxylic acids. J. Lipid Res. 1983; 24: 1140-1147.
  43. Del Rosso J.Q., Lehman P.A., Raney S.G. Impact of order of application of moisturizers on percutaneous absorption kinetics: evaluation of sequential application of moisturizer lotions and azelaic acid gel 15% using a human skin model. Cutis. 2009; 83: 119-124.
  44. Mingrone G., Greco A., Nazzaro-Porro M., Passi S. Toxicity of azelaic acid. Drugs Exp. Clin. Res. 1983; 9:447-455.
  45. Topert M., Rach P., Siegmund F. Pharmacology and toxicology of azelaic acid. Acta Derm. Venereol. [Suppl.] (Stockh). 1989; 143: 14-19.
  46. Bertuzzi A., Gandolfi A., Salinari S., et al. Pharmacokinetic analysis of azelaic acid disodium salt. A proposed substrate for total parenteral nutrition. Clin. Pharmacokinet. 1991; 20: 411-419.
  47. Willshaw H.E., Rubinstein K. Azelaic acid in the treatment of ocular and adnexal malignant melanoma. Br. J. Ophthalmol. 1983; 67: 54-57.
  48. Gavicchini S., Gaputo R. Long-term treatment of acne with 20% azelaic cream. Acta Derm. Venereol. [Suppl.] (Stockh). 1989; 143: 40-44.
  49. Verallo-Rowell V.M., Verallo V., Graupe K., et al. Doubleblind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta Derm. Venereol. [Suppl.] (Stockh). 1989; 143: 58-61.
  50. Graupe K., Cunliffe W.J., Gollnick H.P., Zaumseil R.P. Efficacy and safety of topical azelaic acid (20 percent cream): an overview of results from European clinical trials and experimental reports. Cutis. 1996; 57: 20-35.
  51. Ortonne J.P., Lacour J.P. Assessment of the phototoxicity of azelaic acid using the modified method of Kaidbey and Kligman. Nouv. Dermatol. 1992; 11: 490-495.
  52. Ferguson J., Johnson B.E. Retinoid associated phototoxicity and photosensitivity. Pharmacol. Ther. 1989; 40: 123-135.
  53. Onoue S., Seto Y., Gandy G., Yamada S. Drug induced phototoxicity; an early in vitro identification of phototoxic potential of new drug entities in drug discovery and development. Curr. Drug Saf. 2009; 4: 123-136.
  54. Thielitz A., Lux A., Wiede A., Kropf S., Papakonstantinou E., Gollnick H. A randomized investigator-blind parallel-group study to assess efficacy and safety of azelaic acid 15% gel vs. adapalene 0.1% gel in the treatment and maintenance treatment of female adult acne. J. Eur. Acad. Dermatol. Venereol. 2015; 29(4): 789-796.
  55. Gollnick H.P., Graupe K., Zaumseil R.P. Azelaic acid 15% gel in the treatment of acne vulgaris. Combined results of two double-blind clinical comparative studies. J. Dtsch. Dermatol. Ges. 2004; 2(10): 841-847.
  56. Webster G. Combination azelaic acid therapy for acne vulgaris. J. Am. Acad. Dermatol. 2000; 43: S47-50.
  57. Hjorth N., Graupe K. Azelaic acid for the treatment of acne: a clinical comparison with oral tetracycline. Acta Derm. Vene-reol [Suppl.] (Stockh). 1989; 143: 45-48.
  58. Gollnick H., Graupe K. Azelaic acid for the treatment of acne: comparative trials. J. Dermatol. Treat. 1989; 1: 27-30.
  59. Батыршина С.В., Гордеева А.М., Богданова М.А., Булгакова Д.Р. Эффективностьгеляскиноренв наружной терапии больных угревой болезью и розацеа. Вестник дерматологии и венерологии. 2004; 6: 3-6
  60. Pazoki-Toroudi H., Nilforoushzadeh MA., Ajami M., Jaffary F., Aboutaleb N., Nassiri-Kashani M., Firooz A. Combination of azelaic acid 5% and clindamycin 2% for the treatment of acne vulgaris. Cutan Ocul. Toxicol. 2011 Dec; 30(4): 286-291.
  61. Pazoki-Toroudi H., Nassiri-Kashani M., Tabatabaie H., Ajami M., Habibey R., Shizarpour M., Babakoohi S., Rahshenas M., Firooz A. Combination of azelaic acid 5% and erythromycin 2% in the treatment of acne vulgaris. J. Dermatolog. Treat. 2010 May; 21(3): 212-216.
  62. Пантелеева Г.А. Гель скинорен в терапии акне. Вестник дерматологии и венерологии. 2005; 1: 62-63
  63. Перламутров Ю.Н., Ольховская К.Б. Скинорен гель в терапии и профилактике акне. Клиническая дерматология и венерология. 2007; 4: 40-43
  64. Юцковская Я.А., Маркелова Е.В., Таран М.Г., Ковальчук Е.В., Рахманова С.Н. Азелаиновая кислота в наружном лечении угревой болезни легкой и средней степеней тяжести. Клиническая дерматология и венерология. 2011; 5: 60-69
  65. Матушевская Е.В., Свирщевская Е.В. Азелаиновая кислота в практике врача-дерматолога и косметолога. Клиническая дерматология и венерология. 2014; 5: 11-17
  66. Стаценко А.В., Горбунов Ю.Г., Хайрутдинов В.Р., Шестопалов Н.Е., Антонова О.В. Опыт применения азелаиновой кислоты в терапии больных акне. Вестник дерматологии и венерологии. 2014; 5: 100-105
  67. Самцов А.В. Новое в изучении акне у женщин. Вестник дерматологии и венерологии 2014; (1): 64-68
  68. Монахов К.Н., Домбровская Д.К. Комплексная наружная терапия вульгарных угрей. Вестник дерматологии и венерологии. 2012; 3: 104-10
  69. Катханова О.А., Катханов А.М. Акне с позиции дерматолога и косметолога. Вестник дерматологии и венерологии 2014; 4: 75-82
  70. Матушевская Е.В., Свиршевская Е.В. Эффективность и безопасность микронизированных лекарственных препаратов и их применение в дерматологической практике. Клиническая дерматология и венерология. 2015; 14(5): 410
  71. Bulbake U., Doppalapudi S., Kommineni N., Khan W. Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics. 2017; 9(2). doi: 10.3390/pharmaceutics9020012

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies